Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Daratumumab · Darzalex

Monoclonal antibody · Kills target cells, directed at CD38 and multiple myeloma cells · developed by Janssen Biotech

Approved FDA, Nov 2015
JNJ Developer
2 Registered trials

What is Daratumumab?

Daratumumab is an IgG1κ human monoclonal antibody that binds CD38, a transmembrane glycoprotein on hematopoietic cells including myeloma cells. It kills CD38-expressing tumor cells through apoptosis induced by Fc-mediated cross-linking, complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and phagocytosis, and it decreases CD38-positive regulatory T cells, B cells and myeloid-derived suppressor cells. It is studied in plasma cell disorders.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Darzalex
Drug type
Monoclonal antibody
Targets
CD38, multiple myeloma cells
Mechanism
Kills target cells, directed at CD38 and multiple myeloma cells
Pathways
apoptosis, complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis
Therapy area
Oncology
Developer
Janssen Biotech (JNJ)
FDA status
Approved as Darzalex (November 16, 2015), BLA761036 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 8, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07649525 Phase 3 Multiple Myeloma (MM) Recruiting JNJ
NCT07075510 Phase 1/2 Plasma Cell Disorder Recruiting JNJ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Plasma Cell Disorder

Other drugs acting on CD38

More from Janssen Biotech

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the JNJ page.

Follow JNJ, the company behind Daratumumab

See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JNJ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.